Greetings

Thank you for visiting us.

Since its establishment in 2015, PT CKD OTTO Pharmaceuticals (CKD OTTO Pharma) has committed to significant contributions and social responsibilities based on its vision – “To provide patients with better access to high-quality, cost-effective medicines in key therapeutic areas.” 

Our steadfast commitment to excellence reflected in our compliance with cGMP (Current Good Manufacturing Practice) standard and obtaining of Halal certificate and ISO 14001:2015. Besides, we are delighted to introduce our state-of-the-art facilities and operating system exclusively dedicated to Cytotoxic Oncology Injection production in Indonesia.

Apart from our main focus of business area in Cytotoxic oncology products, we are also developing a new business of Biosimilar products with sufficient technology and marketing resources from Korea.

Our founding mission is deeply rooted in our major shareholder in Korea – “Better Life Through Better Medicine.” We are unwaveringly dedicated to advancing our business consistently by upholding social significant importance.

We sincerely hope for your support in achieving our vision and mission together.

Baik, Sang Hyun